a-1 Antitrypsin (AAT) is a serine proteinase inhibitor secreted from hepatocytes and traversed to the lung, where it protects elastin from degradation by neutrophil elastase. Serum AAT concentration below 0.5 g l À1 (11 mM) can cause panacinar emphysema due to destruction of lung elastin fibers. AAT deficiency is the secondmost common lung disease and accounts for 3% of all early deaths due to obstructive pulmonary disease. 1 Given the limited treatment options for AAT deficiency, gene therapy represents a promising treatment for long-term correction of this metabolic disorder. Administration of vectors such as adeno-associated virus (AAV), adenovirus and helper-dependent adenovirus to the liver or muscle achieved stable therapeutic expression of human AAT (hAAT) in small and large animal models. [1] [2] [3] [4] [5] Interestingly, no B cell response to the hAAT transgene product was detected in these studies. However, there is a considerable lack of information on the cytotoxic T lymphocyte (CTL) response to hAAT. The fact that hAAT expression is stable suggests that Figure 1 Peptide antigens were from a chemically synthesized library consisting of 82 different 15-mers overlapping by 10 amino acids with the preceding peptide and spanning the entire mature hAAT protein (Mimotopes, Victoria, Australia). Peptide pools were prepared as 10 consecutive peptides per pool, resulting in 8 pools of 10 peptides each and 2 pools of 11 peptides. E4-deleted replication deficient HAdV-5 vector expressing hAAT under the control of the cytomegalovirus (CMV) early promoter was described previously.
11 C57BL/6 mice (n ¼ 3) were immunized by intramuscular injection of 5 Â 10 10 particles of HAdV-5-hAAT. Eight days later, splenocytes were stimulated ex vivo with the hAAT-specific peptide pools (2 mg ml À1 ) (a), peptides #41 and #42, and predicted 9-mer (FALVNYIFF) (2 mg ml À1 ) (b) or dose-decreasing concentrations of FALVNYIFF varying from 2 to 1.5 Â 10 À5 mg ml À1 (c) for 18 h at 37 1C, 5% CO 2 and then subjected to the IFN-g ELISPOT assay (BD Biosciences Pharmingen, San Diego, CA, USA). The cells were seeded at 10 5 or 5 Â 10 5 cells per well. The controls were: no peptide (negative) and phorbol myristate acetate/ionomycin (PMA/I) (positive). For the PMA/I control, cells were seeded at 2 Â 10 3 per well. Spots were detected with the AEC substrate set (BD Biosciences) and counted using the AID ELISPOT reader system (Cell Technology, Columbia, MD, USA). CTLs may either be absent or functionally impaired. Moreover, the hAAT protein itself may have tolerogenic immune properties, since it has recently been shown to induce tolerance to insulin-producing b cells in non-obese diabetic mice and to protect transplanted islet allografts from rejection through the induction of regulatory T cells. 6, 7 These observations underscore the need to analyze the ensuing CTL response to hAAT and its modulation by gene transfer vectors, especially since AAV encoding hAAT is currently being pursued in human clinical trials. 8 In this study, we report identification of an immunodominant cytotoxic T lymphocyte epitope of hAAT restricted by H2-D b in C57BL/6 mice that allows us to further characterize the adaptive immune responses after hAAT gene transfer. Mice were immunized intramuscularly with a human adenovirus 5 vector expressing hAAT (HAdV-5-hAAT). At day 8 after immunization, splenocytes were isolated and stimulated ex vivo with eight peptide pools that corresponded to the entire hAAT protein. Activation of cells was analyzed by interferon (IFN)-g production using the ELISPOT assay. Figure 1a shows that pools 1 and 2 elicited robust specific IFN-g responses, indicating that HAdV-5 vector can generate a potent T-cell response to hAAT. To identify the exact 15-mer peptide sequence(s) responsible for T-cell activation, all 22 individual 15-mer peptides contained in these pools were screened. As a result, two 15-mer peptides, #41 (DRDTVFALVNYIFFK) and #42 (FALVNYIFFKGK-WER), which shared an overlapping 10 amino-acid sequence, were identified (Figure 1b) .
The immunodominant epitope was identified using two different prediction programs-HLA-BINDBio-Informatics and Molecular Analysis Section, 9 and SYFPEITHI. 10 The highest-scoring candidate epitope sequence as predicted by both HLA-BIND-Bio-Informatics and Molecular Analysis Section and SYFPEITHI was FALVNYIFF restricted by the H2-D b major histocompatibility complex (MHC) class I molecule. This 9-mer peptide epitope activated a strong T-cell response that was equal to splenocytes stimulated with pools 1 and 2, and with peptides #41 and #42 (Figure 1b) . We also evaluated the affinity of FALVNYIFF binding to the H2-D b MHC molecule by stimulating the splenocytes from mice treated intramuscularly with HAdV-5-hAAT. T-cell responses started to decline below concentration levels of 5 Â 10 À4 mg ml À1 and reached background values at concentrations of 3 Â 10 À5 mg ml
À1
( Figure 1c ), indicating that this 9-mer had a strong binding affinity for the MHC molecule.
To define the T-cell subsets that produced IFN-g in response to antigen, splenocytes isolated from HAdV-5-hAAT treated mice were stimulated ex vivo with FALVNYIFF and analyzed by intracellular cytokine staining. Indeed the T-cell response after stimulation with FALVNYIFF was found to be mediated by CD8 cells with no activation of CD4 cells (Figure 2) . Importantly, we demonstrate that, in spite of the evidence of hAAT acting as an immunomodulatory protein, potent CTL responses can be measured in C57BL/6 mice following gene transfer with adenoviral vectors. These data, including the identification of an epitope restricted by an allele found in the most commonly used strain of mice, should help to pave the way for similar analysis of T-cell responses at the single-cell level in gene transfer trials using hAAT.
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Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA E-mail: wilsonjm@mail.med.upenn.edu 10 particles of HAdV-5-hAAT. Eight days later, splenocytes were stimulated ex vivo with pools 1 and 2, peptides #41 and #42, and FALVNYIFF (2 mg ml À1 ) for 6 h at 37 1C, 10% CO 2 in the presence of 1 mg ml À1 Brefeldin A (GolgiPlug, BD Biosciences) and 20 ng ml À1 of interleukin (IL)-2 (Fitzgerald Industries International, Concord, MA, USA). The cells were then stained with PECy7-labeled anti-mouse CD8 antibody and FITC-labeled anti-mouse CD4 antibody (eBioscience, San Diego, CA, USA). For intracellular cytokine staining, cells were stained with an APC-labeled antimouse IFN-g antibody (eBioscience). Cells were analyzed on a Cytomics FC500 flow cytometer (Beckman-Coulter, Fullerton, CA, USA) and the data were analyzed using FlowJo software (Treestar, Ashland, OR, USA). Numbers within density plots indicate percent CD8 + IFN-g + or CD4 + IFN-g + cells.
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